| Item Type | Name |
|
Academic Article
|
The risks of thyroidectomy: words of caution for referring physicians.
|
|
Academic Article
|
Outcome after treatment of high-risk papillary and non-H?rthle-cell follicular thyroid carcinoma.
|
|
Academic Article
|
Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients.
|
|
Academic Article
|
How should you choose a thyroid surgeon?
|
|
Academic Article
|
Thyroid carcinoma.
|
|
Academic Article
|
Thyroid carcinoma.
|
|
Academic Article
|
A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal.
|
|
Academic Article
|
Nasolacrimal duct obstruction associated with radioactive iodine therapy for thyroid carcinoma.
|
|
Academic Article
|
Prognostic factors in patients with H?rthle cell neoplasms of the thyroid.
|
|
Academic Article
|
Thyroid carcinoma.
|
|
Academic Article
|
Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.
|
|
Academic Article
|
Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma.
|
|
Academic Article
|
Postoperative radiotherapy for advanced medullary thyroid cancer--local disease control in the modern era.
|
|
Academic Article
|
Early clinical studies of novel therapies for thyroid cancers.
|
|
Academic Article
|
Motesanib diphosphate in progressive differentiated thyroid cancer.
|
|
Academic Article
|
Diabetes insipidus and panhypopituitarism due to intrasellar metastasis from medullary thyroid cancer.
|
|
Academic Article
|
Preventable reoperations for persistent and recurrent papillary thyroid carcinoma.
|
|
Academic Article
|
Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer.
|
|
Academic Article
|
The successful use of sorafenib to treat pediatric papillary thyroid carcinoma.
|
|
Academic Article
|
Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma.
|
|
Academic Article
|
Molecularly targeted therapies for thyroid cancers.
|
|
Academic Article
|
Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience.
|
|
Academic Article
|
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
|
|
Academic Article
|
Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy.
|
|
Academic Article
|
Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances.
|
|
Academic Article
|
Not so fast on the thyroidectomy--response to Eloy, et al.
|
|
Academic Article
|
Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
|
|
Academic Article
|
Cytotoxic chemotherapy for differentiated thyroid carcinoma.
|
|
Academic Article
|
Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
|
|
Academic Article
|
Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer.
|
|
Academic Article
|
Inhibition of pituitary tumor-transforming gene-1 in thyroid cancer cells by drugs that decrease specificity proteins.
|
|
Academic Article
|
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
|
|
Academic Article
|
Preoperative lateral neck ultrasonography as a long-term outcome predictor in papillary thyroid cancer.
|
|
Academic Article
|
Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer.
|
|
Academic Article
|
RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors.
|
|
Academic Article
|
Outcomes of patients with differentiated thyroid carcinoma following initial therapy.
|
|
Academic Article
|
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study.
|
|
Academic Article
|
Management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
|
|
Academic Article
|
The role of recombinant human thyrotropin for diagnostic monitoring of patients with differentiated thyroid cancer.
|
|
Academic Article
|
Can serum thyroglobulin levels predict patient outcome after treatment of differentiated thyroid carcinoma?
|
|
Academic Article
|
New approaches to therapy of thyroid malignancies.
|
|
Academic Article
|
Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification.
|
|
Academic Article
|
Four patients with cutaneous metastases from medullary thyroid cancer.
|
|
Academic Article
|
Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment.
|
|
Academic Article
|
Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma.
|
|
Academic Article
|
Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers.
|
|
Academic Article
|
Recurrence after treatment of micropapillary thyroid cancer.
|
|
Academic Article
|
Tyrosine kinase inhibitors and the thyroid.
|
|
Academic Article
|
Long-term eradication of locally recurrent invasive follicular thyroid carcinoma after taxane-based concomitant chemoradiotherapy.
|
|
Academic Article
|
Should papillary thyroid carcinoma be observed?: a word of caution.
|
|
Academic Article
|
Targeted therapy of thyroid cancer.
|
|
Academic Article
|
Medullary carcinoma.
|
|
Academic Article
|
Targeted therapies for thyroid tumors.
|
|
Academic Article
|
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
|
|
Academic Article
|
Applying new clinicopathological characteristics to prognostication in advanced thyroid carcinoma.
|
|
Academic Article
|
Radioiodine therapy in patients with stage I differentiated thyroid cancer.
|
|
Academic Article
|
Thyroid carcinoma.
|
|
Academic Article
|
The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring.
|
|
Academic Article
|
Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer.
|
|
Academic Article
|
Diagnosis and management of differentiated thyroid cancer using molecular biology.
|
|
Academic Article
|
Long-term outcome of comprehensive central compartment dissection in patients with recurrent/persistent papillary thyroid carcinoma.
|
|
Academic Article
|
In papillary thyroid cancer, preoperative central neck ultrasound detects only macroscopic surgical disease, but negative findings predict excellent long-term regional control and survival.
|
|
Academic Article
|
Emerging treatments in thyroid cancer.
|
|
Academic Article
|
Evolving approaches to patients with advanced differentiated thyroid cancer.
|
|
Academic Article
|
Toward a standard clinicopathologic staging approach for differentiated thyroid carcinoma.
|
|
Academic Article
|
Adjuvant therapy and long-term management of differentiated thyroid carcinoma.
|
|
Academic Article
|
The management of metastatic differentiated thyroid carcinoma.
|
|
Academic Article
|
Optimizing the outcomes of adjuvant radioiodine therapy in differentiated thyroid carcinoma.
|
|
Academic Article
|
Socioeconomic factors and the presentation, management, and outcome of patients with differentiated thyroid carcinoma.
|
|
Academic Article
|
Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship.
|
|
Academic Article
|
Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients.
|
|
Academic Article
|
Phase II study of celecoxib in metastatic differentiated thyroid carcinoma.
|
|
Academic Article
|
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
|
|
Academic Article
|
Development and initial validation of the thyroid cancer module of the M. D. Anderson Symptom Inventory.
|
|
Academic Article
|
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
|
|
Academic Article
|
Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer.
|
|
Concept
|
Thyroid Neoplasms
|
|
Academic Article
|
Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.
|
|
Academic Article
|
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
|
|
Academic Article
|
Cabozantinib in progressive medullary thyroid cancer.
|
|
Academic Article
|
Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations.
|
|
Academic Article
|
Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib.
|
|
Academic Article
|
Summary of proceedings of the second World Congress on Thyroid Cancer.
|
|
Academic Article
|
Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer.
|
|
Academic Article
|
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
|
|
Academic Article
|
A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.
|
|
Academic Article
|
Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.
|
|
Academic Article
|
Thyroid carcinoma, version 2.2014.
|
|
Academic Article
|
BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer.
|
|
Academic Article
|
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
|
|
Academic Article
|
New frontiers and treatment paradigms for thyroid carcinoma.
|
|
Academic Article
|
Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis.
|
|
Academic Article
|
Unique characteristics and outcomes of patients diagnosed with both primary thyroid and primary renal cell carcinoma.
|
|
Academic Article
|
A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
|
|
Academic Article
|
Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012.
|
|
Academic Article
|
Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study.
|
|
Academic Article
|
Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis.
|
|
Academic Article
|
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.
|
|
Academic Article
|
Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer.
|
|
Academic Article
|
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
|
|
Academic Article
|
Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine
|
|
Academic Article
|
Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer
|
|
Academic Article
|
Overview of radioactive iodine-resistant differentiated thyroid cancer
|
|
Academic Article
|
Medullary Thyroid Carcinoma Associated with Germline RETK666N Mutation
|
|
Academic Article
|
Why thyroid cancer?
|
|
Academic Article
|
Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer
|
|
Academic Article
|
Molecular mechanisms in thyroid cancer biology
|
|
Academic Article
|
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer
|
|
Academic Article
|
Reassessing the NTCTCS staging systems for differentiated thyroid cancer, including age at diagnosis
|
|
Academic Article
|
Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer (The Journal of Clinical Endocrinology and Metabolism (2010) 95, (5018-5027))
|
|
Academic Article
|
Thyroid cancer
|
|
Academic Article
|
A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer
|
|
Academic Article
|
Cancer disparities and thyroid carcinoma
|
|
Academic Article
|
Thyroid Cancer
|
|
Academic Article
|
Efficacy of the natural clay, calcium aluminosilicate anti-diarrheal, in reducing medullary thyroid cancer-related diarrhea and its effects on quality of life
|
|
Academic Article
|
Detection and prognostic significance of circulating tumor cells in patients with metastatic thyroid cancer
|
|
Academic Article
|
Comprehensive genomic profiling of clinically advanced medullary thyroid carcinoma
|
|
Academic Article
|
Erratum to "Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma" [Hum Pathol 40 (2009) 827-833] (DOI
|
|
Academic Article
|
Bone metastases and skeletal-related events in medullary thyroid carcinoma
|
|
Academic Article
|
Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer
|
|
Academic Article
|
Efficacy and tolerability of vemurafenib in patients with BRAFV600E positive papillary thyroid cancer
|
|
Academic Article
|
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
|
|
Academic Article
|
Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
|
|
Academic Article
|
Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.
|
|
Academic Article
|
Detection and Prognostic Significance of Circulating Tumor Cells in Patients With Metastatic Thyroid Cancer.
|
|
Academic Article
|
Follicular cell-derived thyroid cancer.
|
|
Academic Article
|
Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma.
|
|
Academic Article
|
American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.
|
|
Academic Article
|
Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer.
|
|
Academic Article
|
Medullary Thyroid Carcinoma Associated with Germline RETK666N Mutation.
|
|
Academic Article
|
Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.
|
|
Academic Article
|
Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid.
|
|
Academic Article
|
Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.
|
|
Academic Article
|
Pioglitazone Therapy of PAX8-PPAR? Fusion Protein Thyroid Carcinoma.
|
|
Academic Article
|
Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
|
|
Academic Article
|
No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial.
|
|
Academic Article
|
Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma.
|
|
Academic Article
|
Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging Seventh and Eighth Editions.
|
|
Academic Article
|
Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.
|
|
Academic Article
|
Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry.
|
|
Academic Article
|
Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling.
|
|
Academic Article
|
Novel Drug Treatments of Progressive Radioiodine-Refractory Differentiated Thyroid Cancer.
|
|
Academic Article
|
Combinations of Tyrosine Kinase Inhibitor and ERAD Inhibitor Promote Oxidative Stress-Induced Apoptosis through ATF4 and KLF9 in Medullary Thyroid Cancer.
|
|
Concept
|
Thyroid Carcinoma, Anaplastic
|
|
Academic Article
|
A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.
|
|
Academic Article
|
EVOLUTION OF TARGETED THERAPIES FOR THYROID CARCINOMA.
|
|
Academic Article
|
The De Novo Detection of Anti-Thyroglobulin Antibodies and Differentiated Thyroid Cancer Recurrence.
|
|
Academic Article
|
Response to Ros?rio and Souza C?rtes re: "The De Novo Detection of Anti-Thyroglobulin Antibodies and Differentiated Thyroid Cancer Recurrence".
|
|
Academic Article
|
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.
|
|
Academic Article
|
Distant Metastases From Childhood Differentiated Thyroid Carcinoma: Clinical Course and Mutational Landscape.
|
|
Academic Article
|
ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of RET, VEGFR2, and IGFBP2.
|
|
Academic Article
|
Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib.
|
|
Academic Article
|
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer.
|
|
Academic Article
|
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.
|
|
Academic Article
|
Non-functional water clear cell parathyroid carcinoma masquerading as medullary thyroid carcinoma.
|
|
Academic Article
|
Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial.
|
|
Academic Article
|
Redifferentiation Therapy-Returning to Our Roots in a Post-Kinase Inhibitor World.
|
|
Academic Article
|
Molecular mechanisms of resistance to kinase inhibitors and redifferentiation in thyroid cancers.
|
|
Academic Article
|
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
|
|
Academic Article
|
Challenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care: an international mixed-method study.
|
|
Academic Article
|
Challenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study.
|
|
Academic Article
|
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
|